Once daily MMX mesalazine for the treatment of mild‐to‐moderate ulcerative colitis: a phase II, dose‐ranging study

Summary Background SPD476 (MMX™ mesalazine), is a novel, once daily, high‐strength mesalazine formulation (1.2 g/tablet) that utilizes Multi Matrix System™ (MMX) technology to delay and extend delivery of the active drug throughout the colon. Aim To assess the safety and efficacy of MMX mesalazine...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Alimentary pharmacology & therapeutics 2006-10, Vol.24 (7), p.1087-1097
Hauptverfasser:	D'HAENS, G., HOMMES, D., ENGELS, L., BAERT, F., VAN DER WAAIJ, L., CONNOR, P., RAMAGE, J., DEWIT, O., PALMEN, M., STEPHENSON, D., JOSEPH, R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Anti-Inflammatory Agents, Non-Steroidal - administration & dosage Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics Biological and medical sciences Colitis, Ulcerative - drug therapy Digestive system Double-Blind Method Drug Administration Schedule Female Gastroenterology. Liver. Pancreas. Abdomen Humans Male Medical sciences Mesalamine - administration & dosage Mesalamine - pharmacokinetics Middle Aged Other diseases. Semiology Pharmacology. Drug treatments Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!